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Effects of Lead and Natriuretic Hormone
on Kinetics of Sodium-Potassium-
Activated Adenosine Triphosphatase:
Possible Relevance to Hypertension
by Elmar Weiler,* Farhad Khalil-Manesh,* and
Harvey Gonick*t
Inhibition of vascular smooth muscle sodium-potassium-activiated adenosine triphosphatase (Na-
K-ATPase) has been postulated as a central mechanism in enhancing vascular contractility. In the
present study, kinetics ofinhibition of Na-K-ATPase by lead, ouabain, and natriuretic hormone (NH)
was studied in a purified hog cerebral cortex enzyme preparation. Determination of I50 values for
lead, ouabain, and NH revealed that NH is the most potent inhibitor of the enzyme system (0.8 x
10-6 M ouabain equivalents). Kinetic analyses indicated that lead and NH exhibited different
inhibitory mechanisms. The inhibition by lead was noncompetitive with respect to potassium and
competitive with respect to sodium and MgATP. Natriuretic hormone was noncompetitive with
respect to potassium, uncompetitive with respect to MgATP, and exhibited no inhibitory effect with
respect to sodium. Synergism between lead and NH in the inhibition of Na-K-ATPase raises the
possibility that lead may be a contributoryfactor in hypertension via this mechanism.
Introduction
Epidemiological studies performed both in the
United States (1) and in Great Britain (2) have sug-
gested a correlation between blood pressure and blood
lead within the range of blood lead levels seen in the
normal population. The prevalence of hypertension in
industrially exposed workers has been a matter of
controversy. Studies performed by Cramer and
Dahlberg in 1966 (3) showed no difference in the
incidence of hypertension in workers directly exposed
to lead as compared to age-matched workers in the same
plant who had minimal lead exposure. More recent
studies by de Kort et al. (4) and Kirby et al. (5)
demonstrated a positive relationship between blood
lead and blood pressure in lead-exposed populations.
Thus, the issue has been raised that lead may be a pos-
sible causative or contributory factor in hypertension.
Lead, like many other heavy metals (vanadium,
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mercury, cadmium, uranium) (6-9) is a potent in-
hibitor of the membrane transport enzyme sodium-
potassium-activated adenosine triphosphatase (Na-K-
ATPase, E. C. 3.6.1.3.). This effect of lead, if exerted on
vascular smooth muscle, might produce enhanced
vascular contractility. Within the past few years, there
has been considerable interest in the possibility that a
circulating transport enzyme inhibitor [the putative
hypothalamic-renal natriuretic hormone (NH)]
might be a major cause of essential hypertension via
the same mechanism (10-12). A hypothesis advanced
by Blaustein et al. (11) is that inhibition of the vas-
cular smooth muscle sodium pump by NH leads to
increased intracellular calcium concentrations, thus
enhancing vascular responsiveness to the vasocon-
strictive hormones norepinephrine and angiotensin
II.
If lead and NH could be shown to inhibit Na-K-
ATPase by different mechanisms, then the possibility
exists that lead might act to increase vascular con-
tractility by synergizing with NH in inhibiting the
vascular smooth muscle sodium pump. The goals of
the present study were first to contrast the kinetics of
inhibition of highly purified Na-K-ATPase by leadWEILER, KHALIL-MANESH, AND GONICK
and a semi-purified plasma Na-K-ATPase inhibitor,
(NH), with the known specific inhibitor of Na-K-
ATPase, ouabain, and second to explore the possibility
of synergistic inhibition of the enzyme by lead and
NH.
Methods
Purification of Natriuretic Hormone
from Human Plasma
Separation of low molecular weight NH from high
molecular weight material was achieved by passing
the plasma sample from a hypertensive patient
through an Amicon YM 2 (1 kilodalton cutoff) mem-
brane at 20 psi. For further purification of the low
molecular weight material, the filtrate was passed
through a SEP-PAK cartridge and eluted with
acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA)
as described in an earlier publication (13). The fraction
eluting between 0% ACN and 20% ACN was lyophilized
and stored for kinetic studies. Concentration of
inhibitor was expressed as ouabain-equivalents (13).
Lead acetate used for the kinetic studies was purchased
from Fisher Scientific (Fair Lawn, NJ).
Na-K-ATPase Inhibition Assay
In these experiments a purified Na-K-ATPase from
hog cerebral cortex was employed, purchased from
Sigma Chemical (St. Louis, MO). The incubation
tubes contained a substrate solution providing final
concentrations of 1 mM ATP; 1 mM Mg; 10 mM
imidazole-HCl buffer, pH 7.2; 100 mM Na; 20 mM K;
and 1 mM ethylene glycol-bis-(P-aminoethyl ether)
N,N' tetraacetic acid (EGTA). The tubes were incubated
at 370C for 5 min. The reaction was started by adding
0.025 mL of enzyme preparation (25 mg/mL). The
incubation was stopped after 10 min by adding ice-cold
trichloracetic acid (TCA). After centrifugation (1700g x
5 min), 0.5 mL of supernatant was assayed for
inorganic phosphate by the method of Fiske and
Subbarow (14). In all instances, enzyme inhibition
was expressed as gmole Pi/mg protein/hr.
For determination of I50, i.e., the amount of
inhibitor necessary for 50% enzyme inhibition, serial
dilutions of the purified low molecular weight plasma
NH were prepared. For comparison, ouabain and lead
were dissolved in water to result in final concen-
trations ranging from 4 x 10V M to 4 x 10-3 M ouabain
and 5x 10-5M to 5 x 104M Pb.
To further characterize the inhibitory activities of
lead, ouabain, and NH, kinetic studies were performed
with concentrations of potassium ranging from 0.125
mM to 5.0 mM, sodium ranging from 5 mM to 120
mM, and MgATP ranging from 0.25 mM to 3.0 mM,
in the presence of constant amounts of lead, ouabain,
and NH. For the MgATP studies, the ratio between Mg
and ATP molar concentrations was maintained at 1:1.
Michaelis-Menten parameters were calculated from the
conventional Lineweaver-Burk plot.
Synergy
In order to determine whether lead and NH were
synergistic inhibitors of Na-K-ATPase, a lead dose-
response curve was first established. The combined
effects of lead and NH were assayed in the presence of
two different doses ofNH. The low dose ofNH produced
2% inhibition of the enzyme system, whereas the high
dose yielded 12% inhibition.
Results
Lead, ouabain, and NH were found to be potent
inhibitors of the Na-K-ATPase enzyme system. The I50
values for each substance are shown in Table 1.
Kinetic Studies
Potassium. The effects of varying concentrations
of potassium on Na-K-ATPase activity in the presence
oflead (5 x 10-5M), ouabain (4 x 10-9M), and NH (6.9 x
10-9 M) are shown in Figure 1. The inhibition of Na-
K-ATPase by ouabain was found to be competitive with
respect to potassium, whereas the inhibitory effects of
NH and lead were found to be noncompetitive.
Sodium. With sodium as the variable sustrate, the
kinetic analysis revealed that lead (2.5 x 10-5 M) is a
competitive inhibitor (Fig. 2), whereas NH exhibited
no inhibitory effect.
Magnesium Adenosine Triphosphate
(MgATP). With MgATP as the variable substrate, ki-
netic analysis revealed that lead is a competitive in-
hibitor; NH (1.3 x 10-i) exhibited uncompetitive inhi-
bition (Fig. 3). The Km and Vmax values are listed in
Tables 2 and 3.
Synergy
Figure 4 displays the dose-related inhibition of Na-
K-ATPase in the presence of increasing lead concen-
trations ranging from 0.1 x 10-4 M to 5 x 10-4 M. In the
presence of low dose NH, the inhibition curve is shifted
to the left, i.e., inhibition is increased. In the presence of
high dose NH, a further leftward shift of the Na-K-
ATPase inhibition curve was observed. In both in-
stances, the increment of inhibition produced by add-
Table 1. Determination of 150 values for inhibitors
of Na-K-ATPase.
Substance 150, Ma
Ouabain 2 x 10-6
Lead 80 x 106
NH 0.8 x 106
aThe substrate concentrations for lead and ouabain are expressed as
M, whereas the concentration for NH is expressed as M ouabain
equivalent.
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ing NH was more than would be predicted by a simple
addition effect.
2.4
2.0
1.6
1/ V 1.2
0.8
0.4
-4.0
* Enzyme
v Ouabain
o NH
Pb
4.0 8.0
1 / [K]
12.0 16.0
Discussion
The primary function of the membrane-bound Na-
K-ATPase enzyme system is the active transport of
sodium and potassium (15,16). This enzyme system is
also involved in salt and water homeostasis (17), the
transport of nonelectrolytes (18), and the secretion of
potassium and hydrogen by kidney tubules (18). The
activity of the Na-K-ATPase enzyme system is affected
by a variety of hormones, including mineralo- and
glucocorticoids (19,20), thyroid hormone (21),
insulin (22,23), catecholamines (24), and NH (25,26),
as well as trace metals [e.g., lead, vanadium, mercury,
uranium, cadmium, silver (8,9,27)1. This interaction
2.0,
1.6
1.2
1/ V
0.8
0.4-
-1.0
X. Pb
o NH
* Enzyme
0.5 1.0 2.0
1/[MgATPI
3.0 4.0
FIGURE 1. Lineweaver-Burk plot ofkinetics of inhibition ofNa-K-ATPase
by lead (5 x 105 M), ouabain (4 x 109 M), and NH (0.69 x 109 M
ouabain equivalents) with potassium as the variable substrate.
1.4
1.2
1.0
1/ V 0.8
0.6
0.4
0.2
FIGURE 3. Lineweaver-Burk plot ofkinetics of inhibition of Na-K-ATPase
by lead (5 x 105 M) and NH (1.3 x 1i07 M ouabain equivalents) with
MgATP as the variable substrate.
* Enzyme
- Pb
0.1 0.2 0.3 0.4 0.5
1/[Na]
FIGuRE 2. Lineweaver-Burk plot ofkinetics of inhibition of Na-K-ATPase by lead (25 x 10 6 M) with sodium as the variable substrate.
-0.1
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Table 2. Km values for inhibitors ofNa-K-ATPase.
Km, mM
Substrate K Na MgATP
Enzyme 0.48 34.9 2.69
Lead 0.44 96.8 6.64
NH 1.61
Ouabain 0.50
Table 3. V. values for inhibitors ofNa-K-ATPase.
VM., imole Pi/mgprotein/hr
Substrate K Na MgATP
Enzyme 4.65 17.54 20.16
Lead 3.48 17.30 18.42
NH 2.30 10.13
Ouabain 4.77
c
.2
z
0)
0 0
a.
1.
z
Pb concentration
FIGURE 4. Inhibition of Na-K-ATPase by lead in the presence and
absence of low dose and high dose NH. The inhibitory effect of low
dose NH alone was 2%; the inhibitory effect of high dose NH alone
was 12% (plotted adjacent to y-axis).
of metals with Na-K-ATPase may have physiological as
well as toxicological significance.
Na-K-ATPase has been classified as a sulffhydryl (SH)
enzyme, in part because of its inhibition by mercu-
rials (28). Lead, as a metal that reacts with SH groups,
would also be predicted to act as a Na-K-ATPase in-
hibitor. Kramer et al. (9) found that in renal cortical
tissue homogenates, Na-K-ATPase was inhibited by
50% at a lead concentration of 7 x 10-i M. Similar
results were reported by Nechay and Saunders (7).
These investigators showed that the concentration for
50% inhibition of Na-K-ATPase ranged from 6 to 8 x
10-5 M in both microsomes and tissue homogenates.
The homogenate did not contain any protective sub-
stances that ameliorated Na-K-ATPase inhibition, as
had been reported for mercury (8). Both studies
demonstrated that lead caused a reversible inhibition
of the enzyme system. Ethylenediaminetetraacetic acid
(EDTA) prevents or reverses lead-induced inhibition
of Na-K-ATPase (7). Kramer et al. (9) demonstrated
that lead is a competitive inhibitor with respect to its
substrate ATP. From earlier studies by Tice (29), it
would appear that lead competes with magnesium for
chelation by ATP. Lead is also known to inhibit Na-K-
ATPase at its sodium-sensitive site (7). In the present
study, which employed a purified hog cerebral cortex
Na-K-ATPase enzyme preparation, we also found that
50% inhibition of the Na-K-ATPase enzyme system was
achieved at a lead concentration of 8 x 10- M. The
inhibition of Na-K-ATPase by lead was found to be
noncompetitive with respect to potassium, but com-
petitive with respect to sodium and MgATP.
Endogenous inhibitors of Na-K-ATPase have been
isolated from both plasma and urine by differing
methodologies. Thus, the NH studied by various lab-
oratories may consist of similar or different sub-
stances. Kramer et al. (30), studying a semi-purified
urinary inhibitor, described the NH inhibition of Na-
K-ATPase as noncompetitive with respect to potassium.
Crabos et al. (31) reported that NH, also isolated from
urine, inhibited Na-K-ATPase noncompetitively with
respect to ATP. Inhibition of the enzyme system was
facilitated by sodium. Ouabain, a digitalis glycoside
and a specific inhibitor of the Na-K-ATPase system, has
been shown to be competitive with respect to potassium
(32) and noncompetitive with respect to ATP (31). In
the present study, we employed a semi-purified NH
preparation derived from plasma of a patient with
essential hypertension to perform kinetic studies. This
NH inhibits Na-K-ATPase in a noncompetitive man-
ner with respect to potassium and uncompetitively
with respect to magnesium. The semi-purified mate-
rial exerted no effect on the sodium site of the enzyme
system. These results clearly demonstrate that NH and
lead differ from each other and also from ouabain in
their Na-K-ATPase inhibitory characteristics.
At present, the role of lead as a contributory factor in
hypertension remains speculative; however, there are
in vitro data that support the possibility that lead en-
hances vascular reactivity. Webb et al. (33) found that
tail arteries from hypertensive male rats exposed to lead
at a dose of 100 ppm showed an increase in maximal
contractile force when tested with the a-adrenergic
agents, norephinephrine and methoxamine. This
finding was attributed to an increase in the intra-
cellular pool of activator calcium in the vascular
smooth muscle cell. Piccini et al. (34) and Favalli et al.
(35) found that calcium was necessary in the
perfusion solution for lead to exert an effect on vascular
contractility of the isolated rat tail artery. Further-
more, tissue calcium was increased in the presence of
lead, an effect that could be explained by the inhibitory
effect oflead on the vascular smooth muscle membrane
Na-K-ATPase system, as predicted by the Blaustein
hypothesis (11). As lead and NH have a synergistic
effect on this enzyme system, one possible action oflead
may be to potentiate vascular reactivity in genetically
susceptible individuals. Such a hypothesis is
supported by observations of Cloix et al. (36) that some
normotensive individuals with a family history of
hypertension have elevated levels ofNH.
As hypertension is a multifactorial complex dis-
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order, it is unlikely that a single hormone or toxin can
account for the entire pathogenesis. A more plausible
outcome is that many substances will be found to be
contributory factors and the interplay between these
substances will determine whether a given individual
develops a sustained increase in blood pressure.
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